Thanks @ddwn, I missed Dr Amy Lighters news last week, but it is significant so I think its worth mentioning. In layman's terms after receiving an intestine transplant a patient started developing complications that were approaching graft rejection, and because of his medical history steroids could not be used. Unusually permission was sought from FDA to use Remestemcell as a first line therapy, and the patient was cured. No steroids. Cells were both IV and also injected directly at the inflammation site.This result ultimately supports the use of MSC's instead of steroids for GvHD. That would have a major impact in the market size ( 2- 4x) the SRaGvHD market, but be cautious as this was the first person treated ever in this fashion.
The evidence and fantastic results continue to mount, exactly what shareholders need. Conclusions below from a Brittish Journal Dec 21.
This report describes the successful use of remestemcel-L, an ex vivo expanded allogeneic bone marrow MSC product, to treat a patient with an intestinal transplant who presented with evidence of acute intestinal graft rejection, and questions surrounding an infectious pulmonary process, EBV viraemia, recurrent norovirus excretion in stool, and recurrent C. difficile infections. There were no adverse or serious adverse events, and there was a complete clinical, endoscopic, and histological recovery of the presenting evidence of graft rejection.Although this treatment algorithm has been used in only one patient to date, the authors felt it was important to highlight MSCs as a potential therapeutic agent for patients who present with allograft rejection in the setting of concurrent infectious complications. Although the true efficacy of this treatment strategy remains unknown, its safety has now been well described across numerous clinical trials to date. Thus, consideration may be given in the appropriate context to increase clinical experience with this proposed treatment algorithm.
MSB Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)